HomeNewsFDA Extends Expiration Date for Sure Plenty of EpiPen
Posted in News on 22nd August 2018
The FDA emphasized that these products should continue to be stored as directed on the label to ensure patient safety

The FDA emphasized that these products should continue to be stored as directed on the label to ensure patient safety

The Food and Drug Administration (FDA) has extended the expiration date of certain lots of Mylan’s EpiPen (epinephrine) Auto-Injector 0.3mg by 4 months past the labeled date. 

This date modification beyond the approved 20-month shelf life was based an FDA review of product stability data submitted by Mylan. Several factors contributed to the product’s limited availability in certain areas of the US, including regional supply disruptions and manufacturer issues. Specifically, Mylan cited intermittent supply constraints due to manufacturing delays from their partner, Meridian Medical Technologies, a subsidiary of Pfizer. Continual supply from Meridian is still ongoing and Mylan is expediting shipment to wholesalers upon receipt. Meridian also manufactures EpiPen Jr 0.15mg Auto-Injectors and the authorized generic versions of these strengths. 

The full list of EpiPen Auto-Injectors and Epinephrine Injection, USP Auto-Injectors 0.3mg with extended expiration dates can be found here. Patients with product from these batch numbers will be able to use them through the new use dates provided.

“We’ve completed the necessary reviews of the data to extend the expiration date by four months for specific lots of EpiPen that are expired or close to expiring. We’re hopeful this action will ensure patients have access to this important medication and provide additional peace-of-mind to parents as the agency works with the manufacturer to increase supply,” said Janet Woodcock, MD, director of the FDA’s Center for Drug Evaluation and Research.

Related Post for Emergex indicators MoU with Brazil’s Fiocruz for improvement of viral vaccines

Cerevance begins dosing in Part I scientific trial of CVN424 for therapy of Parkinson’s illness
Psychiatric Hostile Results of Illness-Modifying Therapies Assessed in MS Sufferers
Lumos acquires license for LUM-201 drug that promotes secretion of development hormone
Optimistic Outcomes for Soliris in Neuromyelitis Optica Spectrum Dysfunction Trial
Emergex indicators MoU with Brazil’s Fiocruz for improvement of viral vaccines